Featured Research

from universities, journals, and other organizations

Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's

Date:
October 5, 2012
Source:
Alzheimer Research Forum Foundation
Summary:
A small company with roots in Singapore and Scotland plans to test a relatively unknown compound in clinical trials for a type of dementia that strongly affects behavior.

Remberฎ -- the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease -- has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

TauRx Therapeutics, a Singaporean-Scottish biotech company, reformulated Remberฎ to improve absorption and tolerability, and will test its modified oral compound, LMTX, in bvFTD patients at 25 to 30 sites worldwide. Pending ethics review and approvals, the 12-month bvFTD trial is expected to begin enrolling in November or December. The company also plans to launch two Phase 3 trials in AD in late 2012.

The TauRx molecule has roused researchers' curiosity on a number of fronts. It is believed to be the only drug in clinical testing that breaks up aggregates of tau, the protein that forms neurofibrillary tangles in Alzheimer's and other neurodegenerative diseases. Even more unusual, it has reached Phase 3 with hardly any published preclinical data. Aside from several talks and posters presented at the International Conferences on Alzheimer's Disease in Chicago and Vienna, which Alzforum reported in 2008 and 2009, very little data on Rember or LMTX is in the public domain. Moreover, scientists had concerns about the design and analysis of the company's earlier Phase 2 trial in AD, some of which are addressed in the upcoming Phase 3 studies. A recent Alzforum story and Q&A with TauRx CEO Claude Wischik describe these developments.


Story Source:

The above story is based on materials provided by Alzheimer Research Forum Foundation. Note: Materials may be edited for content and length.


Cite This Page:

Alzheimer Research Forum Foundation. "Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's." ScienceDaily. ScienceDaily, 5 October 2012. <www.sciencedaily.com/releases/2012/10/121005134627.htm>.
Alzheimer Research Forum Foundation. (2012, October 5). Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2012/10/121005134627.htm
Alzheimer Research Forum Foundation. "Tau drug heads into phase 3 trials in frontotemporal dementia, Alzheimer's." ScienceDaily. www.sciencedaily.com/releases/2012/10/121005134627.htm (accessed September 17, 2014).

Share This



More Mind & Brain News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) — The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) — A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
'Magic Mushrooms' Could Help Smokers Quit

'Magic Mushrooms' Could Help Smokers Quit

Newsy (Sep. 11, 2014) — In a small study, researchers found that the majority of long-time smokers quit after taking psilocybin pills and undergoing therapy sessions. Video provided by Newsy
Powered by NewsLook.com
'Fat Shaming' Might Actually Cause Weight Gain

'Fat Shaming' Might Actually Cause Weight Gain

Newsy (Sep. 11, 2014) — A study for University College London suggests obese people who are discriminated against gain more weight than those who are not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins